4.0 Review

Biomarkers of fungal infection: Expert opinion on the current situation

Journal

REVISTA ESPANOLA DE QUIMIOTERAPIA
Volume 33, Issue 1, Pages 1-10

Publisher

SOCIEDAD ESPANOLA QUIMIOTERAPIA
DOI: 10.37201/req/2260.2019

Keywords

Invasive fungal infections; Intensive Care; Critical Care; Candidemia; Invasive candidiasis; invasive aspergillosis; fungal biomarkers; CAGTA; 1-3 beta-D-Glucan; Mannan; Anti-Mannan; T2Candida; Galactomannan; antifungal stewardship

Funding

  1. company Vircell (Spain)

Ask authors/readers for more resources

The introduction of non-culture-based diagnostic techniques is revolutionizing the world of microbiological diagnosis and infection assessment. Fungi are no exception, and the introduction of biomarkers has opened up enormous expectations for better management of these entities. Biomarkers are diverse, their targets are also diverse and their evaluation has been done preferably in an individualized use and with deficient designs. Less is known about the value of the combined use of biomarkers and the impact of the negativity of two or more biomarkers on antifungal treatment decisions has been poorly studied. Given the paucity of prospective, randomized and definitive studies, we have convened experts from different fields, with an interest in invasive fungal infections, to answer some questions about the current relevant use of fungal biomarkers. This document summarizes the answers of these experts to the different questions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available